Bifikafusp alfa

• Target :

  Interleukin

• Related Pathways :

  Immunology/Inflammation

• Bioactivity :

  Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1].

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  1957239-90-5